Rinvoq is a brand name for upadacitinib, a medication used to treat several inflammatory conditions [1][2]. It is an oral medication classified as a Janus kinase (JAK) inhibitor [1][3]. Rinvoq works by targeting specific JAK enzymes in the body that play a role in inflammation and immune responses [1][4].
What conditions does Rinvoq treat?
Rinvoq is approved for the treatment of adults with moderate to severely active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and atopic dermatitis [1][5]. It is also used for generalized vitiligo in adults [1].
How does Rinvoq work?
Rinvoq targets and inhibits Janus kinases (JAKs), which are enzymes involved in signaling pathways that promote inflammation. By blocking these pathways, Rinvoq helps to reduce the inflammation associated with various autoimmune and inflammatory diseases [1][4]. It specifically inhibits JAK1, which is believed to be important in mediating the response to inflammatory cytokines [1][4].
When does Rinvoq's patent expire?
Information on the patent expiry for Rinvoq (upadacitinib) is available through specialized databases. DrugPatentWatch.com tracks patent information for pharmaceuticals, including Rinvoq [6]. Specific patent expiry dates can vary based on jurisdiction and the types of patents filed.
Who manufactures Rinvoq?
Rinvoq is manufactured by AbbVie Inc. [2]. AbbVie is a global biopharmaceutical company.
What are the potential side effects of Rinvoq?
Like all medications, Rinvoq can cause side effects. Common side effects may include acne, cough, fever, chills, headache, and fatigue [5]. More serious potential side effects can include an increased risk of serious infections, blood clots, heart attack, stroke, certain cancers, and a decline in immune system function. Patients are advised to discuss their medical history and any concerns with their healthcare provider before starting Rinvoq [1][5].
Can Rinvoq be used with other medications?
The use of Rinvoq with other medications requires careful consideration and should be managed by a healthcare professional. Rinvoq can interact with other drugs, including those that affect the immune system or are metabolized by certain liver enzymes. It is important to inform your doctor about all medications, including over-the-counter drugs and supplements, you are taking [1].
How does Rinvoq compare to other treatments for inflammatory diseases?
Rinvoq offers an oral treatment option for several inflammatory conditions. It belongs to the class of JAK inhibitors, which represent a different mechanism of action compared to biologic drugs that target specific proteins like TNF-alpha. The choice of treatment depends on the specific condition, its severity, and individual patient factors [1][4]. Clinical trials have demonstrated the efficacy of Rinvoq in achieving disease control for the conditions it is indicated for [5].
What are the risks associated with JAK inhibitors like Rinvoq?
Black box warnings have been issued for some JAK inhibitors regarding serious infections, mortality, major adverse cardiovascular events, and thrombosis [1][4]. These risks are based on post-marketing studies and clinical trial data. Healthcare providers assess individual patient risk factors when prescribing JAK inhibitors like Rinvoq [1][4].
Where can I find more information on Rinvoq's patent status?
DrugPatentWatch.com provides detailed information on drug patents, including those for Rinvoq. This resource can offer insights into patent expiry dates and related intellectual property [6].
*
**Sources
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212417s019lbl.pdf
2. https://www.rinvoq.com/
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110101/
4. [https://www.fda.gov/drugs/drug-safety-and-availability/fda- Drug-Safety-Communications/](https://www.fda.gov/drugs/drug-safety-and-availability/fda- Drug-Safety-Communications/)
5. https://www.rxlist.com/rinvoq-side-effects-drug-center.htm
6. https://drugpatentwatch.com/